Redmile Group LLC lifted its stake in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 7.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,892,902 shares of the biotechnology company's stock after purchasing an additional 323,100 shares during the period. REGENXBIO comprises about 3.0% of Redmile Group LLC's holdings, making the stock its 10th largest holding. Redmile Group LLC owned about 9.88% of REGENXBIO worth $51,327,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD increased its position in shares of REGENXBIO by 8.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 18,177 shares of the biotechnology company's stock valued at $383,000 after purchasing an additional 1,438 shares during the last quarter. Diversified Trust Co acquired a new stake in REGENXBIO in the second quarter valued at $121,000. Assenagon Asset Management S.A. raised its stake in REGENXBIO by 258.7% in the second quarter. Assenagon Asset Management S.A. now owns 816,384 shares of the biotechnology company's stock valued at $9,552,000 after buying an additional 588,773 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its position in shares of REGENXBIO by 26.3% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 134,190 shares of the biotechnology company's stock worth $1,570,000 after acquiring an additional 27,906 shares in the last quarter. Finally, Louisiana State Employees Retirement System increased its holdings in shares of REGENXBIO by 14.0% in the 2nd quarter. Louisiana State Employees Retirement System now owns 22,800 shares of the biotechnology company's stock valued at $267,000 after acquiring an additional 2,800 shares during the last quarter. 88.08% of the stock is owned by institutional investors and hedge funds.
REGENXBIO Stock Down 4.6 %
RGNX stock traded down $0.42 during trading on Thursday, hitting $8.74. The company had a trading volume of 1,552,077 shares, compared to its average volume of 629,405. REGENXBIO Inc. has a 1-year low of $8.44 and a 1-year high of $28.80. The firm has a 50-day moving average price of $9.83 and a 200-day moving average price of $11.67. The firm has a market cap of $432.98 million, a PE ratio of -1.74 and a beta of 1.24.
Insider Activity
In other news, Director Argeris N. Karabelas sold 10,000 shares of REGENXBIO stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total value of $101,100.00. Following the sale, the director now owns 11,286 shares of the company's stock, valued at $114,101.46. The trade was a 46.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 13.13% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities analysts recently issued reports on the company. StockNews.com raised REGENXBIO from a "sell" rating to a "hold" rating in a report on Friday, September 20th. Chardan Capital restated a "buy" rating and issued a $52.00 target price on shares of REGENXBIO in a report on Wednesday, November 20th. Morgan Stanley reaffirmed an "overweight" rating and issued a $22.00 target price on shares of REGENXBIO in a research report on Friday, November 15th. HC Wainwright reduced their price target on shares of REGENXBIO from $40.00 to $36.00 and set a "buy" rating for the company in a research report on Thursday, November 21st. Finally, Raymond James reaffirmed an "outperform" rating and set a $18.00 price objective on shares of REGENXBIO in a report on Thursday, October 10th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company's stock. Based on data from MarketBeat.com, REGENXBIO currently has an average rating of "Moderate Buy" and a consensus price target of $35.27.
Check Out Our Latest Stock Report on REGENXBIO
About REGENXBIO
(
Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Featured Articles
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
